Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Natural Killer (NK) cells are crucial for innate immunity and cancer surveillance.
• Adoptive transfer of allogeneic NK cells has demonstrated safety and efficacy in hematologic malignancies.
• Current T cell therapies require genetic modification to prevent graft-versus-host disease (GVHD).

Purpose of the Study:

• To review the biology of NK cells relevant to cancer therapy.
• To discuss the development of NK cell therapeutics for leukemia, lymphoma, and myeloma.
• To highlight the advantages of the NK cell platform for off-the-shelf cancer treatments.

Main Methods:

• Review of existing literature on NK cell biology and clinical applications.
• Analysis of clinical data regarding the safety and efficacy of allogeneic NK cell infusions.
• Exploration of novel strategies to enhance NK cell function in the tumor microenvironment.

Main Results:

• Adoptive transfer of allogeneic NK cells is safe, with minimal risk of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
• HLA-mismatched NK cells can be infused without GVHD risk, unlike T cells.
• NK cells offer potential as readily available, "off-the-shelf" therapeutic products.

Conclusions:

• NK cell therapy represents a promising and safe approach for treating hematologic malignancies.
• The inherent safety profile of NK cells, particularly the absence of GVHD, facilitates their development as allogeneic "off-the-shelf" products.
• Future research should focus on enhancing NK cell targeting, persistence, and function within the tumor microenvironment to maximize therapeutic potential.